Results 1 to 10 of about 193,929 (276)
Cytokine release syndrome treated with tocilizumab following ipilimumab–nivolumab combination therapy in advanced renal cell carcinoma [PDF]
IJU Case ReportsIntroduction Cytokine release syndrome is a rare but potentially life‐threatening complication of immune checkpoint inhibitor therapy. Its occurrence in renal cell carcinoma treated with combination therapy is less recognized and poses significant ...
Toru Inoue +6 more
doaj +4 more sources
Cytokine release syndrome [PDF]
Journal for ImmunoTherapy of Cancer, 2018 During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody ...
Alexander Shimabukuro-Vornhagen +8 more
doaj +8 more sources
Rituximab and Cytokine Release Syndrome [PDF]
Case Reports in Oncology, 2012 Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated
Hrishikesh S. Kulkarni +1 more
doaj +3 more sources
Cytokine release syndrome after bronchoalveolar lavage
BMC Pulmonary Medicine, 2023 Background Immunosuppressed bone marrow transplant patients with pulmonary infiltrates routinely undergo bronchoscopy with bronchoalveolar lavage (BAL) to investigate potential etiologies.
Margaret Guerriero +3 more
doaj +3 more sources
Cytokine Release Syndrome: Current Perspectives
ImmunoTargets and Therapy, 2019 Hemant Murthy,1 Madiha Iqbal,1 Julio C Chavez,2 Mohamed A Kharfan-Dabaja1 1Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa,
Murthy H +3 more
doaj +4 more sources
Cytokine release syndrome: grading, modeling, and new therapy [PDF]
Journal of Hematology & Oncology, 2018 Genetically modified T cells that express a chimeric antigen receptor (CAR) are opening a new frontier in cancer immunotherapy. CAR T cells currently are in clinical trials for many cancer types.
Delong Liu, Juanjuan Zhao
doaj +3 more sources
Cytokine release syndrome in solid tumors. [PDF]
CancerAbstractCytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has established guidelines for managing CRS in hematological malignancies, there is a growing need to ...
Synnott D +3 more
europepmc +3 more sources
The Many Faces of Cytokine Release Syndrome-Related Coagulopathy [PDF]
Clinical Hematology International, 2021 Cytokine release syndrome (CRS) has been increasingly recognized in various conditions including the coronavirus disease 2019 (COVID-19). It is not only associated with systemic inflammatory symptoms, but also hematological complications such as ...
Jiasheng Wang, John Doran
doaj +3 more sources
Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations [PDF]
Current OncologyBackground: Cytokine Release Syndrome (CRS) is a hyperinflammatory state triggered by immune therapies like CAR T-cell therapy and bispecific T-cell engagers (BiTEs).
Panos Arvanitis +3 more
doaj +2 more sources
Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome. [PDF]
PLoS Computational BiologyChimeric antigen receptor (CAR)-T cell therapy holds significant potential for cancer treatment, although disease relapse and cytokine release syndrome (CRS) remain as frequent clinical challenges.
Daniela S Santurio +3 more
doaj +2 more sources